Deferoxamine Dosage
For chronic iron overload (transfusion-related hemosiderosis), administer deferoxamine 20-50 mg/kg/day subcutaneously via continuous infusion over 8-14 hours, 5-7 days per week; for acute iron poisoning, give 1,000 mg intramuscularly initially (or intravenously at ≤15 mg/kg/hr if in shock), followed by 500 mg every 4-12 hours, not exceeding 6,000 mg in 24 hours.
Chronic Iron Overload (Transfusion-Related Hemosiderosis)
Subcutaneous Administration (Preferred Route)
The American Heart Association consensus statement 1 and FDA labeling 2, 3 establish clear dosing parameters:
- Standard dosing: 20-50 mg/kg/day administered as a 10% solution via portable pump over 8-14 hours
- Frequency: 5-7 days per week
- Dose titration based on serum ferritin:
- Ferritin <2,000 ng/mL: approximately 25 mg/kg/day
- Ferritin 2,000-3,000 ng/mL: approximately 35 mg/kg/day
- Ferritin >3,000 ng/mL: up to 55 mg/kg/day
The subcutaneous route is preferred because deferoxamine has a very short plasma half-life of approximately 20 minutes 1, necessitating prolonged infusion to maintain therapeutic levels. This route achieves about 80% of the efficacy of intravenous administration while being better tolerated for long-term use 4.
Intravenous Administration
When intensive chelation is needed (particularly in heart failure or severe cardiac iron overload with T2* <6 ms):
- Pediatric patients: 20-40 mg/kg/day over 8-12 hours, maximum 40 mg/kg/day 3
- Adults: 40-50 mg/kg/day over 8-12 hours, maximum 60 mg/kg/day 3
- Infusion rate: Should not exceed 15 mg/kg/hr 2, 3
- Duration: 5-7 days per week
For patients with decompensated heart failure from cardiac iron overload, continuous 24-hour intravenous infusion may be necessary initially 1, with conversion to subcutaneous administration after clinical stabilization 1.
Intramuscular Administration
- Dose: 500-1,000 mg daily, maximum 1,000 mg/day 3
- This route is less commonly used for chronic therapy due to inferior efficacy compared to continuous infusion methods.
Acute Iron Poisoning
Intramuscular Route (Preferred for Stable Patients)
For patients NOT in shock 2, 3:
- Initial dose: 1,000 mg
- Subsequent doses: 500 mg every 4-12 hours based on clinical response
- Maximum: 6,000 mg in 24 hours
Intravenous Route (Only for Cardiovascular Collapse)
- Initial dose: 1,000 mg at a rate NOT exceeding 15 mg/kg/hr
- Subsequent doses: 500 mg over 4-12 hours
- Maximum rate: 125 mg/hr for subsequent doses
- Maximum total: 6,000 mg in 24 hours
Critical safety point: The intravenous route should ONLY be used in cardiovascular collapse because rapid infusion increases risk of hypersensitivity reactions, acute respiratory distress syndrome, and renal toxicity 1, 2. As soon as the patient stabilizes, switch to intramuscular administration 3.
Important Safety Considerations
Dose-Related Toxicity
Serious adverse events occur particularly when using higher doses relative to iron burden 1. This is especially problematic in:
- Pediatric patients with low ferritin levels (risk of growth suppression) 2
- Patients with cardiac failure receiving excessive intravenous doses (risk of ARDS) 1, 2
- Those with renal impairment 2
Required Monitoring
- Ophthalmologic and audiological testing: Mandatory due to risk of sensorineural toxicity 1
- Growth monitoring: Essential in pediatric patients 1, 2
- Renal function: Monitor for acute renal failure and tubular disorders 2
- Infection surveillance: Increased risk of Yersinia and Klebsiella infections 1
Vitamin C Supplementation
Up to 200 mg daily of vitamin C may be given to increase iron availability for chelation 2, but should be delayed for one month after starting deferoxamine and avoided in patients with cardiac failure due to risk of cardiac dysfunction 2.
Contraindications
The evidence consistently supports these dosing regimens across multiple high-quality guidelines [1-1] and FDA labeling [2-3], with research studies [4-5] confirming efficacy and safety when properly dosed and monitored.